The artificial intelligence company in the precision medicine sector, Tempus AI, Inc. (Nasdaq: TEM), has announced that it will report its second quarter financial results for the period ending June 30, 2026, after the U.S. market closes on Thursday, July 30, 2026. The company's management will host a conference call and webcast at 4:30 p.m. Eastern Time that same day to discuss the results and provide a business update.

Tempus AI founder and CEO Eric Lefkofsky and CFO Jim Rogers will co-host the call. Investors can access the live webcast via the company's investor relations website.

According to market analysts, the consensus revenue estimate for Tempus's second quarter is approximately $380 million, representing growth of about 20.6% compared to $315 million in the same period last year. Earnings per share are projected to be -$0.15, showing an improvement from -$0.22 in the prior-year quarter. The company's first-quarter revenue was $348 million, a year-over-year increase of approximately 36%.

Recently, Freedom Capital Markets initiated coverage on Tempus AI with a Hold rating and a $59 price target, highlighting that healthcare AI is one of the fastest-growing technology sub-sectors, with a projected compound annual growth rate of 37% to 43% over the next decade. The company has also announced a research collaboration with a non-profit organization focused on angiosarcoma awareness and has launched the Digital Pathology IMS Open Source Alliance project.